Effects of Fingolimod (Gilenya) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals
- 24 May 2017 Status changed from recruiting to completed.
- 14 Oct 2015 Planned end date changed from 1 Sep 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov.
- 14 Oct 2015 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov.